Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

President Donald Trump's proposed budget cuts to the National Institutes of Health would eventually result in fewer drugs on ...

The Trump administration’s proposed cuts to medical research and health agencies will curtail the development of promising ...

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

As different stocks rise and fall, so do dividend yields, creating a shifting landscape of opportunities for income-oriented ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Recent health news highlights various developments, including Trump's spending bill impacting insurance costs, a major acquisition in the bioscience sector, and GSK's efforts to expand RSV vaccine ...

Amazon AMZN.O said on Friday its healthcare business will be divided into six new units as part of a restructuring effort, in a move that comes after recent top health executive departures. The ...

Chinese biotech shares are surging this year on growing optimism over innovative cancer treatments being licensed to western ...

Hemostats market was valued at US$ 2,884.13 million in 2024 and is projected to hit the market valuation of US$ 4,839.68 million by 2033 at a CAGR of 5.92% during the forecast period 2025–2033.

Pfizer faces adjusted financial forecasts as analysts lower earnings expectations for FY2025, signaling cautious optimism.

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...